The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
Open accessAbstract
BACKGROUND: Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease. DESIGN: Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated i.m. on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology. RESULTS: All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence. CONCLUSIONS: These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,628
Bats Are Natural Reservoirs of SARS-Like Coronaviruses
Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., Wang, H., Crameri, G., Hu, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,560
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
The Severe Acute Respiratory Syndrome
Peiris, J. S. M., Yuen, K. Y., Osterhaus, A. D. M. E., & Stöhr, K. (2003) · New England Journal of Medicine · doi:10.1056/nejmra032498 · Cited by 1,346
Identification of Severe Acute Respiratory Syndrome in Canada
Poutanen, S. M., Low, D. E., Henry, B., Finkelstein, S., Rose, D., Green, K., Tellier, R., Draker, R., Adachi, D., Ayers, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030634 · Cited by 1,132
KAPIKIAN, A. Z., MITCHELL, R. H., CHANOCK, R. M., SHVEDOFF, R. A., & STEWART, C. E. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120954 · Cited by 1,033
A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
Tsang, K. W., Ho, P. L., Ooi, G. C., Yee, W. K., Wang, T., Chan-Yeung, M., Lam, W. K., Seto, W. H., Yam, L. Y., Cheung, T. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030666 · Cited by 1,017
Immunopathogenesis of coronavirus infections: implications for SARS
Dandekar, A. A., & Perlman, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1732 · Cited by 499
Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis
Collins, P. L., & Graham, B. S. (2008) · Journal of Virology · doi:10.1128/jvi.01625-07 · Cited by 486
Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477 · cited 2×
“We and others described a similar immunopathologic reaction in mice vaccinated with a SARS-CoV vaccine and subsequently challenged with SARS-CoV [18,20,21,28].”
BackgroundResultGlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
T cell genetic background determines default T helper phenotype development in vitro.
Hsieh, C. S., Macatonia, S. E., O'Garra, A., & Murphy, K. M. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.2.713 · Cited by 462
Subbarao, K., McAuliffe, J., Vogel, L., Fahle, G., Fischer, S., Tatti, K., Packard, M., Shieh, W.-J., Zaki, S., & Murphy, B. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3572-3577.2004 · Cited by 406
A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease
Polack, F. P., Teng, M. N., L.Collins, P., Prince, G. A., Exner, M., Regele, H., Lirman, D. D., Rabold, R., Hoffman, S. J., Karp, C. L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020781 · Cited by 400
Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R., & Anderson, L. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.2852-2860.1996 · Cited by 364
Critically Ill Patients With Severe Acute Respiratory Syndrome
Fowler, R. A. (2003) · JAMA · doi:10.1001/jama.290.3.367 · Cited by 321
Launois, P., Maillard, I., Pingel, S., Swihart, K. G., Xénarios, I., Acha-Orbea, H., Diggelmann, H., Locksley, R. M., MacDonald, H. R., & Louis, J. A. (1997) · Immunity · doi:10.1016/s1074-7613(00)80342-8 · Cited by 302
Deming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., Whitmore, A., Pickles, R., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 275
Martin, J. E., Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.026 · Cited by 267
Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6337 · Cited by 252
Promotion of B Cell Immune Responses via an Alum-Induced Myeloid Cell Population
Jordan, M. B., Mills, D. M., Kappler, J., Marrack, P., & Cambier, J. C. (2004) · Science · doi:10.1126/science.1089926 · Cited by 248
Tseng, C.-T. K., Huang, C., Newman, P., Wang, N., Narayanan, K., Watts, D. M., Makino, S., Packard, M. M., Zaki, S. R., Chan, T.-S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01702-06 · Cited by 244
Self-citationWeiss, R. C., & Scott, F. W. (1981) · Comparative Immunology, Microbiology and Infectious Diseases · doi:10.1016/0147-9571(81)90003-5 · Cited by 240
Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses.
Gorham, J. D., Güler, M. L., Steen, R. G., Mackey, A. J., Daly, M. J., Frederick, K., Dietrich, W. F., & Murphy, K. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12467 · Cited by 200
Vaccines for Biodefense and Emerging and Neglected Diseases
Barrett, A. D. T., & Stanberry, L. R. (2009) · Cited by 197
Lin, J.-T., Zhang, J.-S., Su, N., Xu, J.-G., Wang, N., Chen, J.-T., Chen, X., Liu, Y.-X., Gao, H., Jia, Y.-P., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200702 · Cited by 167
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease
Castilow, E. M., Olson, M. R., & Varga, S. M. (2007) · Immunologic Research · doi:10.1007/s12026-007-0071-6 · Cited by 153
See, R. H., Zakhartchouk, A. N., Petric, M., Lawrence, D. J., Mok, C. P. Y., Hogan, R. J., Rowe, T., Zitzow, L. A., Karunakaran, K. P., Hitt, M., et al. (2006) · Journal of General Virology · doi:10.1099/vir.0.81579-0 · Cited by 153
Spruth, M., Kistner, O., Savidis-Dacho, H., Hitter, E., Crowe, B. A., Gerenčer, M., Brühl, P., Grillberger, L., Reiter, M., Tauer, C., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.055 · Cited by 121
Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease
Enjuanes, L., DeDiego, M. L., Álvarez, E. A., Deming, D., Sheahan, T., & Baric, R. S. (2007) · Virus Research · doi:10.1016/j.virusres.2007.01.021 · Cited by 119
Lamirande, E. W., DeDiego, M. L., Roberts, A., Jackson, J. P., Álvarez, E. A., Sheahan, T., Shieh, W., Zaki, S. R., Baric, R. S., Enjuanes, L., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00304-08 · Cited by 114
Lu, B., Huang, Y. P., Huang, L., Bao, L., Zheng, Z., Chen, Z., Chen, J., Hu, Q., & Wang, H. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03231.x · Cited by 97
Zhou, Z., Post, P. L., Chubet, R. G., Holtz, K., McPherson, C. E., Petrić, M., & Cox, M. M. J. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.059 · Cited by 89
See, R. H., Petric, M., Lawrence, D. J., Mok, C. P. Y., Rowe, T., Zitzow, L. A., Karunakaran, K. P., Voss, T. G., Brunham, R. C., Gauldie, J., et al. (2008) · Journal of General Virology · doi:10.1099/vir.0.2008/001891-0 · Cited by 85
Lokugamage, K. G., Iwata‐Yoshikawa, N., Ito, N., Watts, D. M., Wyde, P. R., Wang, N., Newman, P. C., Tseng, C.-T. K., Peters, C. J., & Makino, S. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.092 · Cited by 73
Self-citationRoberts, A., Lamirande, E. W., Vogel, L., Baras, B., Goossens, G., Knott, I., Chen, J., Ward, J. M., Vassilev, V. B., & Subbarao, K. (2010) · Viral Immunology · doi:10.1089/vim.2010.0028 · Cited by 68
Mice Susceptible to SARS Coronavirus
Wentworth, D. E., Gillim-Ross, L., Espina, N. G., & Bernard, K. A. (2004) · Emerging infectious diseases · doi:10.3201/eid1007.031119 · Cited by 67
Yoshikawa, N., Yoshikawa, T., Hill, T. E., Huang, C., Watts, D. M., Makino, S., Milligan, G. N., Chan, T., Peters, C. J., & Tseng, C.-T. K. (2009) · Journal of Virology · doi:10.1128/jvi.02272-08 · Cited by 57
Self-citationPower, U. F., Huss, T., Michaud, V., Plotnicky‐Gilquin, H., Bonnefoy, J., & Nguyen, T. N. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12421-12430.2001 · Cited by 52
Du, L., Zhao, G., Chan, C. C. S., Li, L., He, Y., Zhou, Y., Zheng, B., & Jiang, S. (2010) · Viral Immunology · doi:10.1089/vim.2009.0090 · Cited by 46
Kusters, I. C., Matthews, J., & Saluzzo, J. F. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369408-9.00011-1 · Cited by 8
Research works printed but not linked: 2
- YV Liu, 2011, Chimeric severe acute respiratory syndrome coronavirus (SARS CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV., Vaccine, 29, 6606, 10.1016/j.vaccine.2011.06.111 · DOI
- C Protheroe, 2009, A novel histological scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis., Clin Gastroenterol Hepatol 2009, 7, 749, 10.1016/j.cgh.2009.03.022 · doi:10.1016/j.cgh.2009.03.022
Cited by
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Mechanisms of SARS-CoV-2 Transmission and Pathogenesis
Harrison, A. G., Lin, T., & Wang, P. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.10.004 · Cited by 1,186
Metadata
- Authors
- Tseng, C.-T., Sbrana, E., Iwata-Yoshikawa, N., Newman, P. C., Garron, T., Atmar, R. L., Peters, C. J., & Couch, R. B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-20
- Volume
- 7
- Issue
- 4
- Pages
- e35421
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2095633747
- Cited by
- 561
- References
- 44
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Update notices
- correction (2012-08-09)
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.